# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data ...
Jim Cramer recommends caution with Ambiq Micro (AMBQ) and suggests Broadcom (AVGO). He dislikes Albertsons (ACI) and advises se...
HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure (NASDAQ:QURE) with a Buy and raises the price target f...
Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Overweight and raises the price target from $65 to $80.
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...
Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ: QURE) with a Neutral and raises the price target from $13 t...
Mizuho analyst Uy Ear maintains uniQure (NASDAQ: QURE) with a Outperform and raises the price target from $30 to $60.